SCHEMBL14255505

SCHEMBL14255505

COC(=O)c1cc2cccnc2c(=O)c2ccc(Cl)cc12

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.45
▸ NR4A2 P43354 2/20 0.45
▸ PLA2G2A P14555 2/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ ABL1 P00519 1/20 0.44
▸ RXFP1 Q9HBX9 1/20 0.42
▸ KDR P35968 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ MAP2K1 Q02750 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ SLC40A1 Q9NP59 2/20 0.40
▸ IRAK4 Q9NWZ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14255189 0.86 KDM4E (0.53) KDM4EMEN1KMT2AALDH1A1MAP2K1
SCHEMBL14255508 0.82 ABL1 (0.49) CHEK1KDM4ENR4A2PLA2G2AABL1
SCHEMBL14255509 0.81 CHEK1 (0.47) CHEK1KDM4ENR4A2PLA2G2AMEN1
SCHEMBL8878118 0.80 MEN1 (0.46) NR4A2MEN1KMT2AALDH1A1SLC40A1
SCHEMBL14255187 0.79 KDM4E (0.57) KDM4EMEN1KMT2AALDH1A1MAP2K1
SCHEMBL14255504 0.78 CHEK1 (0.44) CHEK1NR4A2PLA2G2AMEN1KMT2A
SCHEMBL24338474 0.77 KDM4E (0.50) KDM4EMEN1KMT2ARXFP1KDR
SCHEMBL13789515 0.76 ALDH1A1 (0.44) KDM4ENR4A2MEN1KMT2AKDR
SCHEMBL13515356 0.74 KDM4E (0.47) KDM4EMEN1KMT2AABL1ALDH1A1
SCHEMBL6182503 0.72 NR4A2 (0.50) KDM4ENR4A2MEN1KMT2AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342016-B2 Farnesyl protein transferase inhibitors as antitumor agents SCHERING CORPORATION (US) 2008-03-11 — — US disclosed
US-7342016-B2 Farnesyl protein transferase inhibitors as antitumor agents SCHERING CORPORATION (US) 2008-03-11 — — US disclosed
Send feedback